A cross-disciplinary Roswell Park Comprehensive Cancer Center team submitted the winning application to establish and house a Data Management and Resource-Sharing Center to serve the Immuno-Oncology Translational Network, which directly responds to the goals of the Moonshot.
On Aug. 26, FDA approved the RAS inhibitor, daraxonrasib, sponsored by Revolution Medicines Inc. and also known as Rasonque, for patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
